EMC7: A Potential Drug Target Or Biomarker (G56851)

Target Name: EMC7

NCBI ID: G56851

EMC7: A Potential Drug Target Or Biomarker

EMC7 (C11orf3) is a gene that has been identified as a potential drug target or biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique genetic mutation has led to a high degree of interest in its potential as a therapeutic target.

EMC7 is a gene that encodes a protein known as E-cadherin, which is a protein that is known to play a role in cell-cell adhesion. E-cadherin is a transmembrane protein that is expressed in many different tissues throughout the body, including epithelial tissues, tissues of the nervous system, and tissues of the immune system.

One of the things that makes EMC7 so interesting as a potential drug target is its unique genetic mutation. EMC7 is missense mutated, which means that a single nucleotide has been changed in a way that alters the way the gene is expressed. This type of mutation can result in a protein that has altered function, or even a protein that is missing entirely.

The missense mutation that has been identified in EMC7 is a substitution of a thymine nucleotide for a guanine nucleotide. This change has caused the protein to have a altered propensity to aggregate, which can lead to a variety of different diseases.

One of the things that makes EMC7 so interesting as a potential drug target is its potential to treat a variety of different diseases. The missense mutation that has been identified in EMC7 has been shown to contribute to a number of different diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

For example, studies have shown that EMC7 is overexpressed in a variety of cancer types, including breast, ovarian, and prostate cancer. This suggests that EMC7 may be a useful target for these types of diseases. Additionally, EMC7 has also been shown to be overexpressed in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that it may be a useful target for these types of diseases as well.

Another potential application of EMC7 as a drug target is its potential to treat autoimmune disorders. The missense mutation that has been identified in EMC7 has been shown to contribute to the development and progression of autoimmune disorders. This suggests that EMC7 may be a useful target for these types of disorders as well.

In addition to its potential as a drug target, EMC7 is also of interest as a biomarker. The missense mutation that has been identified in EMC7 has been shown to be associated with a variety of different diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that EMC7 may be a useful biomarker for these types of diseases as well.

Overall, EMC7 is a gene that has a high degree of interest as a potential drug target or biomarker. Its unique genetic mutation and potential to contribute to a variety of different diseases make it an attractive target for research and development. Further studies are needed to fully understand the potential of EMC7 as a drug and biomarker.

Protein Name: ER Membrane Protein Complex Subunit 7

Functions: Part of the endoplasmic reticulum membrane protein complex (EMC) that enables the energy-independent insertion into endoplasmic reticulum membranes of newly synthesized membrane proteins (PubMed:30415835, PubMed:29809151, PubMed:29242231, PubMed:32459176, PubMed:32439656). Preferentially accommodates proteins with transmembrane domains that are weakly hydrophobic or contain destabilizing features such as charged and aromatic residues (PubMed:30415835, PubMed:29809151, PubMed:29242231). Involved in the cotranslational insertion of multi-pass membrane proteins in which stop-transfer membrane-anchor sequences become ER membrane spanning helices (PubMed:30415835, PubMed:29809151). It is also required for the post-translational insertion of tail-anchored/TA proteins in endoplasmic reticulum membranes (PubMed:29809151, PubMed:29242231). By mediating the proper cotranslational insertion of N-terminal transmembrane domains in an N-exo topology, with translocated N-terminus in the lumen of the ER, controls the topology of multi-pass membrane proteins like the G protein-coupled receptors (PubMed:30415835). By regulating the insertion of various proteins in membranes, it is indirectly involved in many cellular processes (Probable)

More Common Targets